Do Thyroid Meds Cause Cancer? What the Evidence Shows

Levothyroxine, the most commonly prescribed thyroid medication worldwide, has been linked to a modest increase in cancer risk in several large population studies, but those links are far more complicated than they first appear. The underlying thyroid disease itself, the dose of medication, how well blood levels are monitored, and the type of thyroid treatment all shape the picture differently. What research actually shows is not a simple yes-or-no story about pills causing tumors.

What Population Studies Find About Levothyroxine and Cancer

Two of the largest studies on this question come from different countries and reach somewhat different conclusions about the size of the risk. A retrospective study of the Korean population found that levothyroxine users had roughly a 50% higher overall odds of cancer at any site compared to non-users, with especially elevated rates for brain, skin, pancreatic, and breast cancers.¹ A Swedish cohort study covering hundreds of thousands of cancer cases found a much smaller increase: about 6% higher risk in men and 8% higher in women on levothyroxine, though the elevated risk showed up across many different cancer types and was strongest among women.²

That gap matters. A 50% increase and a 6-8% increase are dramatically different findings, and the discrepancy points to a fundamental challenge: these are observational studies that compare people taking thyroid medication to people who are not. The two groups differ in ways that go far beyond their prescription bottles.

Why the Underlying Disease Muddles the Numbers

The single biggest problem with interpreting levothyroxine-cancer studies is what researchers call confounding by indication. People take levothyroxine because they have a thyroid condition, and the thyroid condition itself may be what increases cancer risk, not the drug prescribed to treat it. Hashimoto’s thyroiditis, the most common reason people end up on levothyroxine, is associated with roughly 1.7 times the overall cancer risk compared to people without the condition, and dramatically higher risks for colorectal cancer and thyroid cancer specifically.³ When a study compares levothyroxine users to the general population, it is also comparing people with autoimmune thyroid disease to people without it. Untangling the drug effect from the disease effect is extremely difficult.

Detection bias adds another layer. People with thyroid conditions see doctors more often and get more imaging studies than the average person. A study examining GLP-1 receptor agonist medications found that patients on those drugs received significantly more thyroid ultrasounds, leading to higher rates of incidental thyroid cancer detection rather than a genuine increase in cancer development.⁴ The same surveillance effect applies to thyroid patients in general: the more you look, the more you find. Some proportion of the “excess” cancers seen in levothyroxine users were likely sitting there all along, undetected in people who were never scanned.

The Biological Case for a Real Effect

Despite the confounding issues, there are credible biological reasons to think that thyroid hormones themselves can promote tumor growth. Thyroid hormones, especially T4, bind to a receptor on cell surfaces called integrin αvβ3. When they do, they activate signaling pathways that stimulate cell proliferation and new blood vessel formation in tumors.⁵ In animal experiments, tumors that expressed this receptor grew significantly faster in hyperthyroid mice compared to hypothyroid or normally functioning mice, while tumors lacking the receptor showed no difference based on thyroid hormone levels.⁶

This matters because it suggests the effect is not about levothyroxine as a specific drug molecule but about thyroid hormone levels in the blood. Comprehensive reviews of both laboratory and population data conclude that clinical and subclinical hyperthyroidism is associated with higher cancer risk and worse prognosis, while hypothyroidism may actually slow cancer progression or delay its onset.⁷ Multiple lines of evidence point in the same direction: higher thyroid hormone levels act as mediators for tumor growth and proliferation.⁸

The practical implication is straightforward. The concern is not that the pill itself is toxic or carcinogenic. The concern is that too much thyroid hormone, from any source, can create an environment that is friendlier to cancer cells. That shifts the question from “is levothyroxine dangerous” to “is my dose too high.”

Why Dose and TSH Suppression Change the Picture

Thyroid cancer survivors are sometimes prescribed deliberately high doses of levothyroxine to suppress their TSH, a hormone that could stimulate any remaining thyroid cancer cells. This practice, called TSH suppression therapy, creates something closer to a controlled hyperthyroid state, and the evidence on secondary cancer risk here is more concerning than it is for standard replacement doses.

A nationwide Korean cohort study divided thyroid cancer survivors into dose groups and found a clear gradient. Compared to patients not taking levothyroxine, the lowest-dose group actually showed slightly lower risk of a new primary cancer, while the highest-dose group had about 27% higher risk. The pattern was particularly stark for digestive system cancers: stomach, colorectal, liver, and biliary tract cancers all showed rising risk at higher doses, and pancreatic cancer risk roughly doubled in the highest-dose group.⁹ A separate Korean study after thyroidectomy also found that patients who went on to develop a second cancer had been on higher average daily doses of levothyroxine.¹⁰

This dose-dependent pattern aligns with the biological mechanism and has real clinical consequences. Endocrinologists have long warned about overzealous thyroid hormone replacement, noting that patients receiving suppressive doses should be given the minimal amount needed to accomplish the desired clinical response.¹¹ For a person taking a standard replacement dose that keeps their TSH in the normal range, the risk profile looks substantially different from someone being intentionally suppressed to near-hyperthyroid levels.

Breast Cancer, Colorectal Cancer, and Site-Specific Findings

Breast cancer gets particular attention in the thyroid-medication-and-cancer literature because thyroid conditions and breast cancer are both common in women, making the statistical overlap inevitable. A large Taiwanese population-based study found that levothyroxine use was associated with about a 24% higher breast cancer risk.¹² The Korean population study cited earlier also flagged female breast cancer as elevated. But again, women with autoimmune thyroid disease have hormonal and immune profiles that could independently affect breast cancer risk, so pinning the increase on the medication rather than the disease remains difficult.

Colorectal cancer shows a more reassuring and frankly contradictory picture. One large case-control study found that people who had been taking levothyroxine for more than six years showed no increased colorectal cancer risk at all, with odds ratios sitting right at 1.0.¹³ An earlier study actually found the opposite of what you might expect: levothyroxine use was associated with a roughly 40% lower risk of colorectal cancer even after adjusting for multiple lifestyle and health factors.¹⁴ Meanwhile, the dose-dependent study in thyroid cancer survivors found increased colorectal cancer risk at high suppressive doses. The difference probably lies in how much thyroid hormone is circulating: standard replacement doses keeping someone in the normal range may be neutral or even beneficial, while deliberately elevated levels tell a different story.

Radioactive Iodine Is a Separate Concern

Radioactive iodine (RAI) therapy is a fundamentally different treatment from thyroid hormone pills, but it comes up in the same conversation because many thyroid cancer patients receive both. RAI delivers targeted radiation to thyroid tissue and any remaining thyroid cancer cells, and its cancer risk is a radiation-exposure question rather than a hormone-level question.

For Graves’ disease, RAI treatment appears to increase the progression of thyroid carcinoma in people who already have it, though it does not seem to increase the overall rate at which thyroid cancer develops in the first place.¹⁵ For thyroid cancer patients, the risk of developing a second unrelated cancer depends heavily on cumulative dose. A Korean nationwide study of over 360,000 thyroid cancer surgery patients found no significant increase in second cancers for those receiving 100 mCi or less of RAI, but progressively higher risk at higher cumulative doses: roughly 21% higher risk at 101-200 mCi, 42% higher at 201-300 mCi, and 69% higher above 300 mCi.¹⁶

Younger patients face particular concern. Among pediatric and young adult thyroid cancer survivors followed for a median of 15 years, RAI treatment was associated with roughly 23% higher risk of solid cancers overall and 51% higher risk of blood cancers. The risks grew over time: after 20 years of follow-up, the increase in solid cancers climbed to about 47%, and breast cancer risk rose by nearly half. Researchers estimated that about 6% of solid cancers and 14% of blood cancers in this group could be directly attributed to the RAI treatment.¹⁷ These numbers do not apply to adults receiving single standard-dose treatments, but they underscore why oncologists increasingly weigh the long-term risks before recommending RAI in lower-risk thyroid cancers.

Anti-Thyroid Medications for Hyperthyroidism

People with overactive thyroids take the opposite class of medication: anti-thyroid drugs like methimazole and propylthiouracil, which lower thyroid hormone production. These raise different questions. A study of Graves’ disease patients treated with anti-thyroid drugs found small but statistically significant increases in biliary, pancreatic, prostate, and ovarian cancers, along with a pronounced increase in thyroid cancer risk within the first one to two years of treatment.¹⁸

That thyroid cancer spike early in treatment is suspicious. It looks a lot like detection bias: patients newly diagnosed with Graves’ disease undergo extensive thyroid imaging, and incidental thyroid cancers get caught in the process. A systematic review looking specifically at whether anti-thyroid drugs promote thyroid cancer concluded there was no consistent evidence for a relevant role of these medications in causing thyroid cancer.¹⁹ The elevated rates for other cancer types remain harder to explain and harder to rule out, but the data is thin enough that these findings need replication before anyone should lose sleep over them.

Liothyronine and Calcitonin

Not all thyroid medications are levothyroxine. Liothyronine (synthetic T3) is sometimes prescribed alone or alongside T4, and a study of hypothyroid patients who received liothyronine found no significant difference in overall cancer incidence or breast cancer risk compared to those on T4 alone. If anything, the liothyronine group showed slightly lower cancer mortality, though the confidence intervals were wide enough that this could be a chance finding.²⁰

Calcitonin, a hormone used in treating osteoporosis rather than thyroid disease proper, attracted regulatory attention several years ago over a possible cancer link. Salmon calcitonin formulations were reviewed by European and US regulators after some data suggested a weak association with cancer. A review and meta-analysis concluded that while an association could not be entirely excluded, it was weak and a causal relationship was unlikely, with no cellular mechanism identified that would explain how calcitonin might promote tumors.²¹ European regulators pulled nasal calcitonin sprays from the market as a precaution, but the evidence behind the decision was acknowledged to be thin.

What This Means for People on Thyroid Medication

The American Thyroid Association and the American Association of Clinical Endocrinologists both maintain that levothyroxine is the standard of care for hypothyroidism.²²²³ No major medical society has recommended against levothyroxine use based on cancer concerns. The untreated disease, whether hypothyroidism or hyperthyroidism, carries its own serious health risks including cardiovascular disease, metabolic problems, and reduced quality of life.

The practical takeaway is about dose management rather than drug avoidance. If your levothyroxine dose is calibrated to keep your TSH in the normal range and your thyroid hormone levels are not running high, the evidence does not suggest a meaningful cancer risk from the medication itself. The risk signals emerge when doses push people into subclinically or overtly hyperthyroid territory, particularly in the context of TSH suppression after thyroid cancer. Even in that setting, the tradeoff between preventing thyroid cancer recurrence and slightly raising the risk of a second cancer is one that oncologists and endocrinologists weigh carefully on a case-by-case basis.

Nitrosamine Contamination as a Separate Issue

In recent years, several common medications including some thyroid formulations have been flagged for contamination with nitrosamines, a class of chemicals known to be carcinogenic. These contaminants, including NDMA and NDEA, prompted multiple FDA recalls across drug categories including blood pressure medications, heartburn drugs, and diabetes treatments. Risk modeling suggests that nitrosamine contamination in drugs used long-term can meaningfully increase cancer risks.²⁴ This is a manufacturing quality issue rather than a pharmacological one. It applies to many drug classes, and the FDA maintains a public list of affected products and acceptable intake limits. If you are taking a thyroid medication that has been subject to a recall or reformulation, switching to a non-affected manufacturer addresses the issue.

Medication Adherence and Monitoring

One underappreciated aspect of this conversation is that adherence to thyroid medication is inconsistent. A study of postoperative thyroid cancer patients found that medication adherence was only at an intermediate level, and that patients who felt more confident in understanding their medications were more likely to take them correctly.²⁵ Erratic dosing creates its own problems: skipping doses and then doubling up can cause thyroid hormone levels to swing between too low and too high, and it is the high swings that carry the biological risk signals for tumor promotion. Consistent, properly monitored dosing is arguably more important than worrying about whether the medication class itself carries a cancer risk. If anything, the research we have suggests that the danger lies not in taking thyroid medication but in taking too much or taking it inconsistently.